Five companies reported earnings on Wednesday, May 13, and by the close the divergence between them was sharper than the headlines suggested. Nebius Group (NBIS) raised its full-year contracted power target to at least 4 gigawatts — up from a 3-gigawatt target communicated just three months ago, per the company's Q1 2026 conference call transcript. COMPASS Pathways (CMPS) confirmed a rolling NDA submission is underway for COMP360, its psilocybin therapy for treatment-resistant depression. Kamada (KMDA) reiterated full-year revenue guidance of $200 million to $205 million, absorbing a one-quarter shipment delay that management described as already resolved. Humacyte (HUMA) reported Q1 Symvess sales of $0.5 million against $0. And Gladstone Investment (GAIN) wrapped its fiscal year ending March 31, 2026. The afternoon, in short, was a stress test of how differently the market prices early-stage execution risk versus established commercial traction — and the rate backdrop underneath all of it is not neutral.
The 10-year Treasury yield sits at as of May 11, per FRED, while the 2-year is at . That 10Y-2Y spread of — also per FRED, as of May 12 — is not wide enough to signal a confident growth environment, but it is at least positively sloped, which matters for capital-intensive stories like Nebius and Humacyte where the cost of growth financing is a first-order variable. The effective fed funds rate at , per FRED as of May 11, means the opportunity cost of holding early-stage biotech or pre-revenue AI infrastructure remains real. These five prints have to be evaluated inside that macro frame, not around it.
Nebius's Gigawatt Acceleration Is the Print That Carries the Most Nasdaq Read-Through
Start with the number that moved fastest within the call itself. Three months ago, Nebius was targeting more than 3 gigawatts of contracted power by year-end. As of today's call, the company has already contracted more than 3.5 gigawatts — exceeding the prior target before the year is half over — and has raised its new target to at least 4 gigawatts, per CEO Arkady Volozh's prepared remarks in the Q1 2026 transcript.
The qualitative architecture behind that number is also worth parsing. Owned contracted capacity now accounts for more than 75% of total power, per the transcript — a deliberate full-stack positioning the company argues makes its platform more efficient. The new Pennsylvania site, announced this morning, is designed to support 1.2 gigawatts once fully operational and represents the company's second owned gigawatt-scale U.S. site. Three acquisitions — Tavily, Eigen, and Clarifai — closed this year, each described as bringing inference optimization capabilities. Eigen, per management's characterization citing NVIDIA's own ranking, was recognized as the number-one speed inference provider.
The bull case here is structural: if enterprise AI demand continues to concentrate among vendors who own the full stack from bare-metal to agentic services, the capacity moat Nebius is building has compounding value. The bear case is equally structural: contracted gigawatts are not revenue. Capital intensity at this scale — particularly with the 10-year at 4.42% — means the gap between power contracted and cash generated is a risk that can widen fast if enterprise demand softens or if hyperscaler competition intensifies. This is exactly the kind of divergence our earlier note on Q1 divergence between energy, power, and private credit flagged as the dominant sorting mechanism for this earnings season: execution-stage infrastructure stories command a premium only when the demand signal is unambiguous, and for Nebius, that signal is still forward-looking rather than in the rear-view.
The COMP360 NDA Clock Is Running — and the CNPV Is the Variable the Market May Be Underpricing
COMPASS Pathways delivered what is arguably the most binary near-term catalyst in this batch. The company has begun submitting modules under a rolling NDA for COMP360, its COMP360 psilocybin therapy targeting treatment-resistant depression. The final data set required to complete the submission — Part B data from the 006 trial — is expected in early Q3, per CEO Kabir Nath's remarks in the Q1 2026 transcript. Management described the company as on track to be launch-ready by year-end.
Two structural data points from the transcript deserve attention. First, COMPASS received a Commissioner's National Priority Voucher — a designation that, by management's characterization, enables accelerated engagement with the FDA to compress the review timeline. Second, per the transcript, the company is actively engaging the DEA ahead of the standard 90-day post-approval rescheduling window, citing an executive order that creates the potential for the process to move faster than the statutory baseline. That's a meaningful procedural development for a Schedule I compound moving toward commercialization.
The bear case is clinical-to-commercial translation risk. COMPASS management noted that with only one drug currently approved and used for TRD, the patient identification, prescriber education, and payer coverage infrastructure for this class of therapy is essentially being built from scratch. The bull case is the differentiation argument management pressed hard: COMP360's Phase III data, blinded to an unprecedented 26 weeks for psychiatry trials per the transcript, demonstrated both rapid onset and extended durability — a combination no currently approved TRD drug offers, per management's framing. The historical anchor here is instructive. When Spravato (esketamine) cleared FDA in March 2019 after a similar accelerated-path review for TRD, the initial commercial ramp was slower than the clinical data implied — constrained by REMS requirements and the required in-office administration model. COMP360 faces analogous structural hurdles, and the CNPV designation accelerates regulatory review but does not simplify the commercial infrastructure problem.
Kamada's Guidance Reiteration Carries More Weight Than the Delayed Shipment Made It Look
The read-through on Kamada is cleaner than the Q1 noise suggested. A single delayed shipment — already delivered in April, per CEO Amir London's prepared remarks — suppressed the Q1 print relative to expectations. The company's response was not to trim guidance; it reiterated its full-year revenue target of $200 million to $205 million and adjusted EBITDA of $50 million to $53 million, per the transcript. At the guidance midpoint, that represents 12% revenue growth and 23% adjusted EBITDA growth relative to full-year 2025 results — organic, with no M&A contribution assumed.
The organic growth confidence rests on several pillars described in the call: continued commercialization of six FDA-approved specialty plasma-derived products, biosimilar launches in the Israeli market, expansion of the distribution business into the MENA region, and a ramp in plasma collection across three owned plasma centers aimed at both reducing specialty plasma costs and generating normal source plasma sales revenue. Vertical integration as a cost lever is the most defensible part of the bull case — it doesn't require market share gains, just operational execution on infrastructure already in place.
The caution is around the guidance being back-half weighted by construction. If Q1 was suppressed by a timing event, the company needs Q2 through Q4 to carry meaningfully more weight. That's not unusual, but it does concentrate execution risk in a period where the macro backdrop — particularly for any company with international revenue exposure — remains uncertain. The 46-basis-point yield curve spread signals an economy that is growing but not accelerating. That's a workable environment for a specialty pharma name with stable demand, but it offers no cushion for further shipment disruptions or pricing pressure in the distribution segment.
Humacyte's $0.5 Million Quarter and What Gladstone's Fiscal Year Close Tell You About Stage-Gating Risk
Humacyte's Symvess revenue of $0.5 million in Q1 — compared with $0.1 million in Q1 of the prior year, per the earnings transcript — is an encouraging directional signal that lands alongside a candid acknowledgment from CEO Laura Niklason that the pace of commercial uptake must accelerate. The company's response has been to restructure its commercial and clinical leadership: a new Chief Commercial Officer and a new Chief Surgical Officer were both recently hired, per the transcript, with the latter described as a trailblazer in vascular trauma and peripheral artery disease. Deeper coverage of large integrated delivery networks is also described as a priority.
This is a pattern worth flagging explicitly. Early commercial ramps for novel vascular biologics are historically physician-education constrained rather than market-size constrained. The product's potential audience exists; the question is whether a revamped commercial team can compress the education cycle. At a 3.63% effective fed funds rate, the cost of the runway needed to get from $0.5 million quarters to self-sustaining revenue is not trivial. The bull case is that hiring James Mercadante — described in the transcript as having an extensive track record in vascular and cardiothoracic surgery markets — and Dr. Todd Rasmussen signals a deliberate pivot from a science-led commercialization model to a field-execution model. That is the right pivot for this stage. The bear case is that the pivot is late relative to the funding clock.
Gladstone Investment's Q4 and fiscal year-end print — covering the period ending March 31, 2026 — arrived in the same afternoon wave but belongs to a different risk category entirely. As a business development company with exchange-listed notes (GAINZ, GAINI, GAING) alongside common equity, its relevance today is primarily as a credit-environment read. With the yield curve positively sloped at 46 basis points and the effective fed funds rate at 3.63%, the BDC sector faces a rate environment that is meaningfully different from the zero-lower-bound era — and that shapes both the cost of GAIN's own liabilities and the health of the portfolio companies it holds. Our read on that sector's positioning was sharpest in the PPL, FIS, and Oshkosh Q1 analysis, where the gap between beating the number and sustaining the multiple became the defining question — and it applies equally here.
The forward look coming out of Wednesday's close is three-pronged. For Nebius, the question that carries into Thursday and beyond is whether customer revenue growth is tracking the capacity build — contracted gigawatts without corresponding revenue growth is a story that eventually runs out of multiple. For COMPASS, the early-Q3 arrival of Part B 006 data is the single most important near-term binary; any signal on that timeline — acceleration or delay — will be the dominant share-price driver between now and year-end. For Kamada, the Q2 print will be the first clean read on whether the Q1 delay was genuinely a one-time event or the beginning of a pattern — and the guidance reiteration means management has explicitly staked credibility on that distinction. At these levels, with the 10-year at 4.42% and the yield curve barely positive, none of these stories get the benefit of a low-rate growth story. They have to earn their multiples on execution. Wednesday afternoon told you which ones are moving in that direction.